Zacks Research Analysts Raise Earnings Estimates for EW

Edwards Lifesciences Co. (NYSE:EW) – Equities researchers at Zacks Research upped their Q3 2025 earnings estimates for shares of Edwards Lifesciences in a research note issued to investors on Wednesday, November 20th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $0.60 per share for the quarter, up from their previous estimate of $0.59. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.57 per share.

Several other research firms also recently weighed in on EW. Oppenheimer restated an “outperform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a report on Thursday, September 12th. Truist Financial reduced their target price on Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating on the stock in a research note on Friday, October 25th. UBS Group cut their price target on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a report on Tuesday, September 10th. Citigroup dropped their price objective on Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research report on Tuesday, October 1st. Finally, Jefferies Financial Group lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their target price for the company from $85.00 to $70.00 in a report on Wednesday, September 18th. Seventeen research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences has an average rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Stock Up 1.1 %

EW opened at $71.26 on Monday. The company has a market cap of $42.03 billion, a price-to-earnings ratio of 10.28, a PEG ratio of 3.96 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences has a one year low of $58.93 and a one year high of $96.12. The business’s fifty day moving average is $67.74 and its two-hundred day moving average is $75.48.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the previous year, the firm earned $0.59 earnings per share. The firm’s revenue was up 8.9% on a year-over-year basis.

Institutional Investors Weigh In On Edwards Lifesciences

A number of large investors have recently added to or reduced their stakes in the company. First Community Trust NA purchased a new position in Edwards Lifesciences in the 2nd quarter valued at about $29,000. FSA Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the third quarter worth about $30,000. Prospera Private Wealth LLC purchased a new position in Edwards Lifesciences in the third quarter valued at about $32,000. Avior Wealth Management LLC grew its stake in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares in the last quarter. Finally, Webster Bank N. A. acquired a new stake in Edwards Lifesciences during the 2nd quarter valued at approximately $39,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at $3,077,593.52. This represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,000 shares of company stock valued at $2,657,000. Company insiders own 1.27% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.